Search research articles
Contact Us
Filters
Showing results (101-110 of 110) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 110 results.
International Journal of Cardiology
|
September 20, 2018
Incidence and predictors of bleeding in ACS patients treated with PCI and prasugrel or ticagrelor: An analysis from the RENAMI registry
Fabrizio D'Ascenzo, Alberto Grosso, Emad Abu-Assi, et al.
Revista Espanola De Cardiologia (English Ed.)
|
July 22, 2018
Usefulness of the PARIS Score to Evaluate the Ischemic-hemorrhagic Net Benefit With Ticagrelor and Prasugrel After an Acute Coronary Syndrome
Sergio Raposeiras-Roubín, Berenice Caneiro Queija, Fabrizio D'Ascenzo, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
April 29, 2019
Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI Registry
Ovidio De Filippo, Martina Cortese, Fabrizio D Ascenzo, et al.
The American Journal of Cardiology
|
January 1, 2020
Incidence of Adverse Events at 3 Months Versus at 12 Months After Dual Antiplatelet Therapy Cessation in Patients Treated With Thin Stents With Unprotected Left Main or Coronary Bifurcations
Fabrizio D'Ascenzo, Umberto Barbero, Mohamed Abdirashid, et al.
International Journal of Cardiology
|
April 12, 2019
Daily risk of adverse outcomes in patients undergoing complex lesions revascularization: A subgroup analysis from the RAIN-CARDIOGROUP VII study (veRy thin stents for patients with left mAIn or bifurcatioN in real life)
Carloalberto Biolè, Zenon Huczek, Ivan Nuñez-Gil, et al.
Thrombosis Research
|
June 2, 2018
Anemia in patients with acute coronary syndromes treated with prasugrel or ticagrelor: Insights from the RENAMI registry
Carme Guerrero, Alberto Garay, Albert Ariza-Solé, et al.
International Journal of Cardiology
|
December 2, 2019
Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor
Matteo Bianco, Fabrizio D'ascenzo, Sergio Raposeiras Roubin, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
October 6, 2019
Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries
Mattia Peyracchia, Andrea Saglietto, Carloalberto Biolè, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
September 13, 2019
P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects
Ovidio De Filippo, Fabrizio D'Ascenzo, Sergio Raposeiras-Roubin, et al.
American Heart Journal
|
December 7, 2019
Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries
Fabrizio D'Ascenzo, Carloalberto Biolè, Sergio Raposeiras-Roubin, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 110) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 110 results.
International Journal of Cardiology
|
September 20, 2018
Incidence and predictors of bleeding in ACS patients treated with PCI and prasugrel or ticagrelor: An analysis from the RENAMI registry
Fabrizio D'Ascenzo, Alberto Grosso, Emad Abu-Assi, et al.
Revista Espanola De Cardiologia (English Ed.)
|
July 22, 2018
Usefulness of the PARIS Score to Evaluate the Ischemic-hemorrhagic Net Benefit With Ticagrelor and Prasugrel After an Acute Coronary Syndrome
Sergio Raposeiras-Roubín, Berenice Caneiro Queija, Fabrizio D'Ascenzo, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
April 29, 2019
Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI Registry
Ovidio De Filippo, Martina Cortese, Fabrizio D Ascenzo, et al.
The American Journal of Cardiology
|
January 1, 2020
Incidence of Adverse Events at 3 Months Versus at 12 Months After Dual Antiplatelet Therapy Cessation in Patients Treated With Thin Stents With Unprotected Left Main or Coronary Bifurcations
Fabrizio D'Ascenzo, Umberto Barbero, Mohamed Abdirashid, et al.
International Journal of Cardiology
|
April 12, 2019
Daily risk of adverse outcomes in patients undergoing complex lesions revascularization: A subgroup analysis from the RAIN-CARDIOGROUP VII study (veRy thin stents for patients with left mAIn or bifurcatioN in real life)
Carloalberto Biolè, Zenon Huczek, Ivan Nuñez-Gil, et al.
Thrombosis Research
|
June 2, 2018
Anemia in patients with acute coronary syndromes treated with prasugrel or ticagrelor: Insights from the RENAMI registry
Carme Guerrero, Alberto Garay, Albert Ariza-Solé, et al.
International Journal of Cardiology
|
December 2, 2019
Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor
Matteo Bianco, Fabrizio D'ascenzo, Sergio Raposeiras Roubin, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
October 6, 2019
Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries
Mattia Peyracchia, Andrea Saglietto, Carloalberto Biolè, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
September 13, 2019
P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects
Ovidio De Filippo, Fabrizio D'Ascenzo, Sergio Raposeiras-Roubin, et al.
American Heart Journal
|
December 7, 2019
Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries
Fabrizio D'Ascenzo, Carloalberto Biolè, Sergio Raposeiras-Roubin, et al.
Page
of 11